ABSTRACT
Cell therapy, dened as the administration of stem/ progenitor cells to correct CFTR dysfunction in the lung, is a comparatively new concept. Systemic and topical cell administration routes have been assessed, albeit with limited success. Most recently signicant advances in lung and airway ex vivo bioengineering have been made, which may in the future benet CF patients. Key studies related to cell therapy and bioengineering will also be discussed.
